CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
celecoxib +1 moredrug
Likely dose
Not stated in record
Key inclusion· 7
  • ✓Histologically or cytologically confirmed non-small cell lung cancer
  • ✓Inoperable stage IIB OR unresectable stage IIIA or IIIB disease
  • ✓No evidence of hematogenous metastases
  • ✓Zubrod 2 with >5% weight loss in past 3 months, OR Zubrod 0–1 with <5% weight loss and refuses chemotherapy or medically unable to tolerate combined modality therapy
Key exclusion· 12
  • ✕No prior thoracic radiotherapy
  • ✕No prior neoadjuvant chemotherapy
  • ✕No prior complete or subtotal tumor resection
  • ✕Known hypersensitivity to celecoxib or prior allergic-type reactions to sulfonamides

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00046839
NCT00046839Phase 2Completed
CompareCT.gov

A Phase I/II Trial of a COX-2 Inhibitor, Celebrex (Celecoxib), [National Screening Committee# 719627] With Limited Field Radiation for Intermediate Prognosis Patients With Locally Advanced Non-Small Cell Lung Cancer, With Analysis of Prognostic Factors

Radiation Therapy Oncology Group·interventional·Posted Jan 27, 2003·Updated Nov 17, 2015

In Brief

A Phase 2 clinical trial evaluating celecoxib and radiation therapy for Lung Cancer. Completed, enrolled 21 participants across 44 sites.

Detailed Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor and may make the tumor cells more sensitive to radiation therapy. PURPOSE: Phase I/II trial to study the effectiveness of combining celecoxib with radiation therapy in treating patients who have locally advanced non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartJul 1, 2002
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 9.2 yearsPosted 23.4 years ago

Interventions

celecoxibdrug

radiation therapyradiation